Asset Details
Do you wish to reserve the book?
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
Do you wish to request the book?
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
2019
Overview
ObjectiveEarly diagnosis of natalizumab-related progressive multifocal leucoencephalopathy (NTZ-PML) in multiple sclerosis has been deemed a major priority by the regulatory agencies but has yet to become a reality. The current paper aims to: (1) investigate whether patients with NTZ-PML pass through a prolonged presymptomatic phase with MRI abnormalities, (2) estimate the longitudinal PML lesion volume increase during the presymptomatic phase and (3) estimate the presymptomatic phase length and its impact on therapy duration as a risk stratification parameter.MethodsAll Italian patients who developed NTZ-PML between 2009 and 2018 were included. The data of patients with available prediagnostic MRI were analysed (n=41). Detailed clinical and neuroradiological information was available for each participant.Results(1) PML lesions were detectable in the presymptomatic phase in 32/41 (78%) patients; (ii) the lesion volume increased by 62.8 % for each month spent in the prediagnostic phase; (3) the prediagnostic phase length was 150.8±74.9 days; (4) PML MRI features were detectable before the 24th month of therapy in 31.7 % of patients in our cohort.ConclusionsConsidering the latency of PML clinical manifestation, the presymptomatic phase length supports the usefulness of MRI surveillance every 3–4 months. Early diagnosis could prompt a better outcome for patients due to the relationship between lesion volume and JC virus infection. The insight from this study might also have an impact on risk stratification algorithms, as therapy duration as a parameter of stratification appears to need reassessment.
Publisher
BMJ Publishing Group LTD
Subject
/ Female
/ Humans
/ Immunologic Factors - therapeutic use
/ Italy
/ Lesions
/ Leukoencephalopathy, Progressive Multifocal - diagnostic imaging
/ Leukoencephalopathy, Progressive Multifocal - etiology
/ Leukoencephalopathy, Progressive Multifocal - pathology
/ Male
/ Multiple Sclerosis - diagnostic imaging
/ Multiple Sclerosis - drug therapy
/ Multiple Sclerosis - pathology
/ Natalizumab - therapeutic use
/ NMR
/ Patients
